Baxter (NYSE:BAX) said today that patients treated with automated peritoneal dialysis cyclers and its Sharesource remote patient management platform showed significant reductions in hospitalization rates and hospitalization days.
The results of a study comparing peritoneal dialysis patients managed with Sharesource to those not using the remote platform at home showed a 39% reduction in hospitalizations for home PD patients receiving care and a 54% reduction in length of hospital stay for home dialysis patients requiring inpatient care. It was recently published in Peritoneal Dialysis International.
The study, which consisted of 126 propensity-matched patients using APD therapy with or without remote management through 28 different Baxter Renal Care Services clinics in Colombia, recorded hospitalization rates and hospitalization days over the course of one year.
Sharesouce is designed to allow healthcare providers to securely view patients’ recently completed home dialysis-related treatment data, which is automatically collected after each PD session. After viewing the data, healthcare providers may remotely adjust the patients’ home device settings without requiring a trip to the clinic.
“We firmly believe patients should have access to the therapy options that best meet their clinical and lifestyle needs. We also believe significantly more patients can benefit from home therapy than do today,” Baxter Renal Care general manager Laura Angelini said in a news release. “This study illustrates how innovation, like Sharesource, can assist more patients in successfully performing therapy at home.”
Baxter launched the Sharesource 2.0 telehealth clinical portal in June. The Sharesource platform is available on Baxter’s Amia APD system in Canada and the U.S., the HomeChoice Claria APD systems in several countries across Europe, Asia and Latin America, as well as the Kaguya APD system in Japan.
Shares of BAX were down -0.8% at $86.75 per share in midday trading today.
